Polaryx Therapeutics Completes $10 Million Private Placement to Fund Phase 2 Trial
Polaryx Therapeutics has completed a $10 million private placement equity financing, which will support the launch of its SOTERIA Phase 2 basket trial for PLX-200. The funds are intended to advance clinical development and extend operating runway through Q2 2027.
Tickers: $PLYX